Endometrial Cancer News and Research

RSS

Short-course, higher dose vaginal brachytherapy for endometrial cancer shown to be effective

In a randomized clinical trial, researchers from Huntsman Cancer Institute at the University of Utah (the U) have found that short-course, higher dose vaginal brachytherapy for endometrial cancer had similar effectiveness to more frequent, lower dose sessions.

11 Feb 2025

Hormonal shifts in menopause redefine women’s microbiome and risks

Research explores how menopause-induced hormonal shifts affect the microbiome, influencing oral, gut, and urogenital health, and highlights the potential of personalized interventions to enhance well-being.

15 Jan 2025

Study explores cancer risks of hormonal contraceptives

Many women worry hormonal contraceptives have dangerous side-effects including increased cancer risk. But this perception is often out of proportion with the actual risks.

15 Jan 2025

New NCCN guidelines include expanded genetic risk assessment for various cancers

The National Comprehensive Cancer Network (NCCN) - an alliance of leading cancer centers focusing on maintaining evidence-based expert consensus driven guidelines for care - announces the publication of the expanded NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Genetic/Familial High-Risk Assessment: Breast, Ovarian, Pancreatic, and Prostate.

7 Nov 2024

Inflammatory proteins linked to higher risk of endometrial cancer

Study identifies key inflammatory and immune response proteins linked to endometrial cancer risk through both observational and Mendelian Randomization analyses, revealing the roles of IL-6 and HSD11B1.

1 Oct 2024

ESMO 2024: Promising results in immunotherapy and antibody drug conjugates for gynecological cancers

Studies reported at ESMO 2024 reveal new groups of women with early-stage endometrial and cervical cancers who gain clinically meaningful benefit from adding immunotherapy to current standard treatments, while a first-in-human study found 'promising' antitumor activity with a novel antibody drug conjugate (ADC) targeting the protein claudin 6 in heavily pretreated patients with ovarian and endometrial cancers.

16 Sep 2024

Antibody-drug conjugate shows promise in treating ovarian and endometrial cancers

14 Sep 2024

New cancer drug shows encouraging results in Phase I/II trial

The antibody-drug conjugate (ADC) puxitatug samrotecan (AZD8205) demonstrated a manageable safety profile consistent with similar ADCs and initial efficacy in heavily pretreated patients with advanced or metastatic solid tumors, according to interim data shared today at the 2024 European Society for Medical Oncology (ESMO) Congress by researchers from The University of Texas MD Anderson Cancer Center.

14 Sep 2024

ISM2196: A promising AI-developed WRN inhibitor for advanced metastatic cancers

Insilico Medicine("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the nomination of ISM2196, an AI-driven, potential best-in-class small molecule WRN inhibitor targeting advanced metastatic microsatellite instability (MSI) cancers guided by synthetic lethality strategy.

13 Sep 2024

Breast cancer rises among Asian American and Pacific Islander women

Christina Kashiwada was traveling for work during the summer of 2018 when she noticed a small, itchy lump in her left breast.

4 Sep 2024

Targeted therapy slows endometrial cancer growth in mice models

There may be a way to slow the growth of endometrial cancer through targeted cancer cell therapy, according to new research from the University of Missouri School of Medicine.

21 Aug 2024

FDA accepted PD-L1 inhibitor durvalumab for the treatment of endometrial cancer

On June 14, 2024, the U.S. FDA approved AstraZeneca's Durvalumab (IMFINZI®) for primary advanced or recurrent endometrial cancer with mismatch repair deficiency. Endometrial cancer is the most prevalent gynecologic cancer, with an estimated 66,200 new U.S. cases in 2023.

From Sino Biological Inc. 5 Aug 2024